Is QDEL or RXST more profitable?

RxSight has a net margin of -36.80% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets QuidelOrtho -39.20% 4.88% 1.63% RxSight -36.80% -17.35% -14.70%

Does the media favor QDEL or RXST?

In the previous week, RxSight had 11 more articles in the media than QuidelOrtho. MarketBeat recorded 16 mentions for RxSight and 5 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 1.49 beat RxSight's score of 0.84 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CERS or RXST?

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.51 -$15.63M -$0.03 N/A RxSight $134.48M 2.02 -$38.94M -$1.13 N/A

Is CERS or RXST more profitable?

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% RxSight -36.80% -17.35% -14.70%

Does the media prefer CERS or RXST?

In the previous week, RxSight had 13 more articles in the media than Cerus. MarketBeat recorded 16 mentions for RxSight and 3 mentions for Cerus. Cerus' average media sentiment score of 1.34 beat RxSight's score of 0.84 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is SMTI or RXST more profitable?

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -29.15% 29.72% 2.84% RxSight -36.80% -17.35% -14.70%

Does the media prefer SMTI or RXST?

In the previous week, RxSight had 14 more articles in the media than Sanara MedTech. MarketBeat recorded 16 mentions for RxSight and 2 mentions for Sanara MedTech. RxSight's average media sentiment score of 0.84 beat Sanara MedTech's score of 0.51 indicating that RxSight is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, RXST or EMBC?

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $134.48M 2.02 -$38.94M -$1.13 N/A Embecta $1.08B 0.30 $95.40M $1.48 3.84

Is RXST or EMBC more profitable?

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Embecta 8.59% -19.25% 10.82%

Does the media prefer RXST or EMBC?

In the previous week, RxSight had 13 more articles in the media than Embecta. MarketBeat recorded 16 mentions for RxSight and 3 mentions for Embecta. RxSight's average media sentiment score of 0.84 beat Embecta's score of 0.00 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RXST or OSUR?

In the previous week, RxSight had 13 more articles in the media than OraSure Technologies. MarketBeat recorded 16 mentions for RxSight and 3 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.44 beat RxSight's score of 0.84 indicating that OraSure Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive OraSure Technologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

RxSight (RXST) Competitors

$6.54 -0.49 (-6.97%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$6.52 -0.01 (-0.23%)

As of 05:09 AM Eastern

Compare

RXST vs. QDEL, CERS, SMTI, EMBC, and OSUR

Should you buy RxSight stock or one of its competitors? RxSight's main competitors and comparable companies include QuidelOrtho (QDEL), Cerus (CERS), Sanara MedTech (SMTI), Embecta (EMBC), and OraSure Technologies (OSUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does RxSight compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

QuidelOrtho has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, RxSight has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

QuidelOrtho currently has a consensus price target of $13.63, indicating a potential downside of 2.19%. RxSight has a consensus price target of $8.37, indicating a potential upside of 27.93%. Given RxSight's stronger consensus rating and higher probable upside, analysts plainly believe RxSight is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

RxSight has a net margin of -36.80% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
RxSight	-36.80%	-17.35%	-14.70%

RxSight has lower revenue, but higher earnings than QuidelOrtho. RxSight is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.35	-$1.13B	-$15.41	N/A
RxSight	$134.48M	2.02	-$38.94M	-$1.13	N/A

In the previous week, RxSight had 11 more articles in the media than QuidelOrtho. MarketBeat recorded 16 mentions for RxSight and 5 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 1.49 beat RxSight's score of 0.84 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

RxSight beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.

How does RxSight compare to Cerus?

Cerus (NASDAQ:CERS) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

78.4% of Cerus shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 5.3% of Cerus shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
RxSight	-36.80%	-17.35%	-14.70%

Cerus has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, RxSight has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Cerus presently has a consensus target price of $5.25, suggesting a potential upside of 104.28%. RxSight has a consensus target price of $8.37, suggesting a potential upside of 27.93%. Given Cerus' stronger consensus rating and higher possible upside, research analysts clearly believe Cerus is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.51	-$15.63M	-$0.03	N/A
RxSight	$134.48M	2.02	-$38.94M	-$1.13	N/A

In the previous week, RxSight had 13 more articles in the media than Cerus. MarketBeat recorded 16 mentions for RxSight and 3 mentions for Cerus. Cerus' average media sentiment score of 1.34 beat RxSight's score of 0.84 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cerus beats RxSight on 12 of the 16 factors compared between the two stocks.

How does RxSight compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

In the previous week, RxSight had 14 more articles in the media than Sanara MedTech. MarketBeat recorded 16 mentions for RxSight and 2 mentions for Sanara MedTech. RxSight's average media sentiment score of 0.84 beat Sanara MedTech's score of 0.51 indicating that RxSight is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Sanara MedTech has higher earnings, but lower revenue than RxSight. Sanara MedTech is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.09	-$37.56M	-$3.59	N/A
RxSight	$134.48M	2.02	-$38.94M	-$1.13	N/A

Sanara MedTech has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, RxSight has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 10.1% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
RxSight	-36.80%	-17.35%	-14.70%

Sanara MedTech presently has a consensus target price of $35.00, suggesting a potential upside of 0.81%. RxSight has a consensus target price of $8.37, suggesting a potential upside of 27.93%. Given RxSight's stronger consensus rating and higher possible upside, analysts clearly believe RxSight is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Summary

RxSight beats Sanara MedTech on 9 of the 15 factors compared between the two stocks.

How does RxSight compare to Embecta?

RxSight (NASDAQ:RXST) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

RxSight has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Embecta has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Embecta	8.59%	-19.25%	10.82%

In the previous week, RxSight had 13 more articles in the media than Embecta. MarketBeat recorded 16 mentions for RxSight and 3 mentions for Embecta. RxSight's average media sentiment score of 0.84 beat Embecta's score of 0.00 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.02	-$38.94M	-$1.13	N/A
Embecta	$1.08B	0.30	$95.40M	$1.48	3.84

78.8% of RxSight shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

RxSight presently has a consensus price target of $8.37, indicating a potential upside of 27.93%. Embecta has a consensus price target of $11.00, indicating a potential upside of 93.32%. Given Embecta's higher possible upside, analysts plainly believe Embecta is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Summary

RxSight and Embecta tied by winning 8 of the 16 factors compared between the two stocks.

How does RxSight compare to OraSure Technologies?

RxSight (NASDAQ:RXST) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

RxSight currently has a consensus target price of $8.37, suggesting a potential upside of 27.93%. OraSure Technologies has a consensus target price of $3.00, suggesting a potential downside of 16.20%. Given RxSight's stronger consensus rating and higher possible upside, equities research analysts clearly believe RxSight is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

RxSight has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

In the previous week, RxSight had 13 more articles in the media than OraSure Technologies. MarketBeat recorded 16 mentions for RxSight and 3 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.44 beat RxSight's score of 0.84 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
OraSure Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RxSight has higher revenue and earnings than OraSure Technologies. RxSight is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.02	-$38.94M	-$1.13	N/A
OraSure Technologies	$115.02M	2.15	-$68.73M	-$0.69	N/A

78.8% of RxSight shares are owned by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are owned by institutional investors. 10.1% of RxSight shares are owned by company insiders. Comparatively, 4.7% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

RxSight has a net margin of -36.80% compared to OraSure Technologies' net margin of -43.70%. RxSight's return on equity of -17.35% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
OraSure Technologies	-43.70%	-19.09%	-16.26%

Summary

RxSight beats OraSure Technologies on 11 of the 16 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$292.40M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-5.79	25.92	273.29	25.25
Price / Sales	2.02	73.24	621.79	97.64
Price / Cash	N/A	33.14	77.82	52.26
Price / Book	1.03	6.04	13.08	6.14
Net Income	-$38.94M	$150.03M	$3.47B	$349.01M
7 Day Performance	-7.23%	-1.38%	0.52%	-0.31%
1 Month Performance	4.64%	1.21%	5.63%	0.64%
1 Year Performance	-22.79%	9.83%	25.31%	14.83%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXST RxSight	2.2257 of 5 stars	$6.54 -7.0%	$8.37 +27.9%	-26.4%	$292.40M	$134.48M	N/A	220
QDEL QuidelOrtho	1.8066 of 5 stars	$14.77 +1.9%	$13.63 -7.7%	-49.5%	$1.01B	$2.67B	N/A	6,500
CERS Cerus	2.1488 of 5 stars	$2.77 +2.8%	$5.25 +89.9%	+96.2%	$557.20M	$206.13M	N/A	290	Positive News
SMTI Sanara MedTech	1.2226 of 5 stars	$34.40 +0.1%	$35.00 +1.7%	+3.6%	$316.12M	$103.12M	N/A	60
EMBC Embecta	3.6574 of 5 stars	$4.93 -1.3%	$11.00 +123.4%	-60.2%	$279.62M	$1.02B	3.33	1,850

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors